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ABSTRACT
OBJECTIVE: To determine the prevalence of reagent serology for suspected acute
toxoplasmosis in pregnant women and to describe clinical, laboratory and therapeutic
profiles of mothers and their children.
METHODS: A retrospective study was conducted with IgM-anti-Toxoplasma gondii-
reagent pregnant women and their children who attended the public health system in
the state of Paraná, Southern Brazil, from January 2001 to December 2003. Information
were obtained from clinical, laboratory (ELISA IgM/IgG) and ultrasonographic data
and from interviews with the mothers. To test the homogeneity of the IgM indices in
relation to the treatment used, the Pearson’s Chi-square test was applied. Comparisons
were considered significant at a 5% level.
RESULTS: Two hundred and ninety (1.0%) cases of suspected IgM-reagent infection
were documented, with a prevalence of 10.7 IgM-reagent women per 1,000 births.
Prenatal care started within the first 12 weeks for 214/290; 146/204 were asymptomatic.
Frequent complaints included headaches, visual disturbance and myalgia.
Ultrasonography revealed abnormalities in 13 of 204 pregnancies. Chemoprophylaxis
was administered to 112/227; a single ELISA test supported most decisions to begin
treatment. Pregnant women with IgM indices =2.000 tended to be treated more often.
Among exposed children, 44/208 were serologically followed up and all were IgG-
reagent, and three IgM-reagent cases showed clinical symptoms.
CONCLUSIONS: The existence of pregnant women with laboratorially suspected
acute toxoplasmosis who were not properly followed up, and of fetuses that were not
adequately monitored, shows that basic aspects of the prenatal care are not being
systematically observed. There is need of implementing a surveillance system of
pregnant women and their children exposed to T. gondii.
KEYWORDS: Pregnant women. Toxoplasmosis, epidemiology.
Toxoplasmosis, congenital, prevention & control. Toxoplasmosis,
congenital, diagnosis. Prenatal care. Seroepidemiological studies.
Epidemiological surveillance services.
RESUMO
OBJETIVO: Determinar a prevalência de gestantes com sorologia reagente suspeita
de toxoplasmose aguda e descrever as variáveis maternas e do concepto relacionadas
ao perfil clínico, laboratorial e terapêutico.
MÉTODOS: Estudo retrospectivo com gestantes IgM anti-Toxoplasma gondii
reagentes e conceptos atendidos em serviço público de saúde do Paraná, de janeiro/
2001-dezembro/2003. Foram obtidas informações a partir de dados dos registros
clínicos, laboratoriais (ELISA IgM/IgG), ultrassonográficos e de entrevista materna.
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Para testar a homogeneidade dos indices de IgM em relação ao tratamento usado,
aplicou-se o qui-quadrado de Pearson. O nível de significância adotado foi de 5%.
RESULTADOS: Ocorreram 290 casos (1,0%) IgM reagentes, evidenciando prevalência
de 10,7 gestantes com sorologia reagente a cada 1.000 nascimentos. Duzentos e
quatorze de 290 gestantes iniciaram o pré-natal até a 12ª semana de gestação; 146/
204 foram assintomáticas; cefaléia, distúrbios visuais e mialgia foram queixas
freqüentes; 13/204 gestantes apresentaram anormalidades ao ultrassom; 112/227
gestantes receberam quimioprofilaxia; um único teste ELISA apoiou a maioria das
tomadas de decisão para a quimioprofilaxia. Houve tendência em tratar gestantes
com índices de IgM=2.000. Dentre as crianças expostas, 44/208 tiveram algum
acompanhamento sorológico, das quais todas foram IgG reagentes e três casos IgM
reagentes apresentaram manifestações clínicas.
CONCLUSÕES: A existência de gestantes com suspeita laboratorial de toxoplasmose
aguda não devidamente investigada e de conceptos sem monitoração adequada
evidenciam que aspectos fundamentais da assistência pré-natal não estão sendo
sistematicamente observados. Aponta-se a necessidade de implementar o sistema de
vigilância para gestantes e crianças expostas ao T. gondii.
DESCRITORES: Gestantes. Toxoplasmose, epidemiologia. Toxoplasmose
congênita, prevenção e controle. Toxoplasmose congênita, diagnóstico.
Cuidado pré-natal. Estudos soroepidemiológicos. Serviços de vigilância
epidemiológica.
INTRODUCTION
Toxoplasmosis is a widespread zoonosis caused by
the intracellular parasite Toxoplasma gondii, which
affects up to one-third of the world’s population. This
disease can produce a wide range of clinical mani-
festations or, in most cases, progress asymptomati-
cally.14 Primary infection during gestation may cause
serious neurological damage, blindness and even
fetal death.15,22
The chances of fetal infection by T. gondii increase
with the stage of pregnancy, from 5-15% in the first
half of gestation, to 60-80% in the second half. Con-
versely, the chances of serious lesions and death de-
crease, declining from 70-80% in the first half to less
than 10% in the second half.3 Anti-parasite treatment
of pregnant women can reduce the risk of transmission
to or consequences for the fetus if it is started early.14,22
An important aspect of this disease is the possibility
of reagudization in any phase of life. Tissue damage
can begin during pregnancy and sometimes contin-
ues after birth, during infancy, or later in adulthood,
causing neuropsychomotor and optical sequelae.7,11,15
Because of the persistence of certain classes of anti-
bodies, such as IgM and IgA, and the high sensitivity
of the serological methods currently available, com-
plementary tests are necessary in order to assess more
accurately the chronology of the infection in preg-
nant women.8 However, the risk of congenital trans-
mission may exist not only in cases of seroconver-
sion, but also in cases of suspected infection as de-
tected by elevated mean titers of IgM and/or IgA and
IgG.2,10 Therefore, clinical and serological follow-up
for all neonates of IgM-reagent pregnant women, even
if they are asymptomatic, is recommended.15,18
Brazil is a vast country, with marked differences in
socioeconomic conditions and health care levels
among its population. The performance of programs
for control of congenital toxoplasmosis in different
regions of the country must be assessed.17 In the state
of Paraná, Southern Brazil, IgG anti-T. gondii preva-
lence ranged from 40%4 to 66%5 in 1983 e 1996 re-
spectively, and 1.8% IgM anti-T. gondii seroincidence
in pregnant women has been observed in northern
areas of the state.13
Based on routine laboratory tests during prenatal care,
the objective of the present study was to verify the
prevalence of suspected reagent serology for acute
toxoplasmosis among pregnant women, and to de-
scribe the clinical, laboratory and therapeutic pro-
files of mothers and children suspected to have been
exposed during gestation.
METHODS
An observational, longitudinal and retrospective study
with a dynamic population base, consisting of preg-
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nant women with suspected acute toxoplas-
mosis and their exposed children, was carried
out. These women and their children attended
the public health care services in the north-
western macro-region of the state of Paraná
(Figure), from January 2001 to December
2003. The inclusion criteria were IgM anti-T.
gondii pregnant women in any gestational
trimester and children born from these rea-
gent mothers.
Information about the pregnant women and
their children was gathered from data avail-
able in the public health care laboratory net-
work, medical records, the Prenatal Infor-
mation System (SISPrenatal) database, the
register of pregnant women cared for by the
Family Health Program (PSF), the Sistema
Nacional de Informação de Nascidos Vivos
(SINASC - National Live Birth Information
System) database, and the Sistema Nacional
de Informação sobre Mortalidade (SIM -
National Mortality System). These data were
complemented by interviews. A pre-coded
structured questionnaire was used, collect-
ing data on the residence of the women, pre-
natal care (obstetric history, date of admis-
sion), signs of maternal infection by T. gondii
(clinical, laboratory, ultrasonographic ab-
normalities and treatment) and data on the
newborns (date of birth/death, weight, ges-
tational age, clinical and laboratory findings, care
and treatment).
The diagnostic protocol* for toxoplasmosis in preg-
nant women in the state of Paraná was assessed by the
ELISA technique for IgM and IgG detection during
the first trimester of pregnancy, preferably; it is sug-
gested to confirm IgM positivity by assessing IgA.
Repeating the IgM and IgG in the second and third
trimesters was recommended for non-reagent preg-
nant women. The avidity test was not used by the
studied public health care services. In 2004, the State
Protocol for high-risk pregnancies was revised,** and
in cases of IgM reagents, IgA serology was replaced
by the IgG avidity test to confirm uncertain cases.
The therapeutic plan assumes that there is maternal-
fetal risk of congenital transmission*,** when IgG
and IgM are reagents and the avidity is low. Although
laboratory diagnosis and treatment are provided by
the state, they were not always available.
The laboratory diagnostic method used for pregnant
women and their children was the Microparticle En-
zyme Immunoassay (MEIA) for  anti-T. gondii IgM
and IgG (Abbot Diagnostics AxSYM®). IgM indices
over 0.600 and IgG values over 3.0 IU/mL were con-
sidered as reagent.
The prevalence of pregnant women anti-T. gondii-
IgM-reagent accumulated in the period was calcu-
lated from the number of live births recorded in
SINASC. Cases of congenital toxoplasmosis were
considered to be those newborns with anti-T. gondii-
IgM reagent serology, and those who showed sero-
conversion during the first year of life, regardless of
clinical manifestations. Suspected cases of congeni-
tal toxoplasmosis were those newborns of anti-T.
gondii-IgM-reagent mothers with visual disturbances,
abnormalities of neuropsychomotor development,
and other nonspecific neurological manifestations
without diagnostic confirmation.
The EPI-Data software program version 3.0 was used
for database entry, and the SAS software program ver-
sion 8.2 was used in the result analyses. To test the
homogeneity of the IgM indices in relation to the
*Secretaria de Estado da Saúde do Paraná. Protocolo de gestação de alto risco. 2a ed. Curitiba: SESA; 2002.
**Secretaria de Estado da Saúde do Paraná. Protocolo de gestação de alto risco. 3a ed. Curitiba: SESA; 2004.
Figure - Geographic location and administrative divisions of the
municipalities included in the study, and mean prevalence of anti-T.
gondii IgM in resident pregnant women. State of Paraná, Southern Brazil,
January 2001 to December 2003.
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treatment provided, the Pearson’s Chi-square test was
applied. Comparisons were considered significant at
a 5% significance level.
The study was approved by the Research Ethics Com-
mittee of the Universidade Estadual de Maringá
(COPEP Resolution 196/960).
RESULTS
Of 318 pregnant women with laboratory tests indi-
cating acute toxoplasmosis, 290 met the inclusion
criteria, representing 1.0% of 29,868 pregnancies es-
timated by SISPrenatal during the study period. The
prevalence of IgM-anti-T. gondii reagent was 10.7
per 1,000 live births by SINASC (Figure).
Among these women, 214 (73.9%) had started follow-
up by the 12th week of pregnancy, and 96 (26.1%) be-
tween the 13th and 32nd week. The mean interval be-
tween admission and sampling for the first serology
test in the 290 pregnant women was 17.7 days; for 108
(37.2%) of them it took between zero to seven days,
for 98 (33.8%) between eight and 30 days, and for 84
(29.0%) it was collected after more than a month. For
258 (89%) pregnant women with prenatal information,
more than a month had elapsed between delivery of
the laboratory result and beginning of medical care.
The mean gestational age during collection of the first
blood sample was 11.36±6.09 weeks.
Of 16,686 samples collected for the initial assess-
ment of anti-T. gondii IgM and IgG, 26 were IgM-
reagent, 264 IgM- and IgG-reagent, 10,882 IgG-rea-
gent and 5,740 non-reagent. Among the 290 IgM-
reagent pregnant women, a two-sample serological
follow-up for IgM was carried out in 90 (31%); and in
38 (13.1%) of them a three-sample follow-up was car-
ried out. The majority, 76/90 (84%) and 26/38 (68%)
respectively, remained anti-T. gondii-IgM reagent in
the subsequent samples. The median (0.783; 0.861
and 0.726) and mean (1.130; 1.130 and 0.980) of the
three IgM sample indices were very close. None of
the women studied underwent a laboratory test for
IgA, and no amniotic liquid was tested for fetal infec-
tion by PCR and for inoculation into mice.
The anti-T. gondii-IgG avidity test was performed in
only ten cases (3.4%). Two cases showed low avidity,
one in the third month and the other in the sixth
month of pregnancy, suggesting acute infection. Both
of them were treated with spiramycin. Three cases
showed high avidity, suggesting chronic infection,
and five cases showed inconclusive results.
Clinical and ultrasonographic data were available for
204 of the 290 women (70.3%). Of these, 146 (71.6%)
were asymptomatic. Among women with clinical mani-
festations, the main complaints were intense frontal or
periorbital headaches in 58 (28.4%) cases. There were
concomitant symptoms in 45 (22.0%) cases, who also
presented scotomatous visual disturbance, 35 (17.1%)
with myalgia, and 24 (11.8%) with fever accompanied
by adenomegaly. The ultrasonographies, performed
after the 23rd week of pregnancy in 141 cases (69%),
revealed alterations in 13 cases (6.4%). The alterations
detected were oligohydramnios (5 cases), polyhydram-
nios (2), placental alterations (2), fetal cardiac arrhyth-
mia (1), anencephaly (1), alterations in the cranium (1)
and renal malformations (1). In six of 13 cases that
progressed to fetal loss, congenital T. gondii infection
was not confirmed by serology; however, in four cases,
anatomical-pathological examination revealed
multivisceral autolysis or fetal malformation sugges-
tive of toxoplasmosis. Spiramycin was taken by seven
women with ultrasonographic abnormalities (53.8%).
Three pregnancies continued to term but were still-
born. Among the four live births, there were optical
alterations, cardiac arrhythmia and renal alterations,
and two had no apparent sequelae.
Information on treatment provided was available for
227 (78.3%) of the 290 women: 112 (49.3%) were
prescribed chemoprophylaxis with different therapeu-
tic regimens, and 115 (39.7%) were not treated (Ta-
ble 1). In 27 cases (24.1%), the time elapsed between
sampling for the first serological test and starting
treatment was less than 15 days; in 31 cases (27.7%),
the elapsed time was 15 to 30 days; and in 54 cases
(48.2%), it was more than one month. The prescribed
therapy was administered until the end of gestation
in 64 (57.1%) of the 112 women treated. Side effects
were reported by 27 (24.1%) of them, with the most
frequent complaints related to the gastrointestinal
tract. The prescription of chemoprophylaxis varied
in relation to the initial levels of IgM (Table 2).
Women with IgM indices higher than 2.000 were
treated more frequently than those with indices be-
tween 0.600 and 1.000 (Table 2).
Table 1 - Therapeutic regimens used by anti-T. gondii-IgM-
reagent pregnant women. State of Paraná, Southern Brazil,
January 2001 to December 2003.
Therapeutic regimen Pregnant women
N %
Triple scheme Sp1 intercalated S2 + P3 + FA4 4 1.4
Spiramycin with a 1-week suspension 41 14.1
Spiramycin with a 2-week suspension 48 16.5
Spiramycin continuously 19 6.5
No treatment prescribed 115 39.7
Treatment unknown 63 21.8
Total 290 100.0
1. Spiramycin; 2. Sulfadiazine; 3. Pyrimethamine; 4. Folinic
Acid
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Information on 232 newborns showed that 29 (12.5%)
were premature, 23 (9.9%) were underweight and 180
(77.6%) were normal weight. There were 16 cases
(6.9%) of fetal loss through miscarriages and still-
births, with 5 (31%) showing malformations (anen-
cephaly, agenesis of the limbs, hydrocephalus). Based
on the 26,989 births from SINASC and death records
from SIM, the mortality rate among children (live
births and fetal losses) of IgM-reagent mothers was
0.7 per 1,000 live births.
Of 208 exposed children who could be located during
the first year after birth, 194 (93%) were evaluated in a
pediatric or general clinic, and 55 (26.4%) were re-
ferred to specialty treatment (infectious diseases, oph-
thalmology or neurology). Serological examinations
were performed in 44 (21.1%) children, all anti-T.
gondii-IgG-reagents; in three cases, clinical symptoms
of the disease were found (two with retinochoroiditis
and one with retinochoroiditis, obstructive hydro-
cephalus and calcifications). The incidence rate of the
confirmed cases was 0.1 per 1,000 live births. Only
five children completed the three-sample serological
follow-up. The diagnosis was confirmed in three chil-
dren, promptly from the first sample.
A total of 30 cases showed clinical abnormalities (Ta-
ble 3). Optical alterations occurred in 16 cases (7.7%),
with three (1.4%) having serious optical lesions
(retinochoroiditis), and 13 (6.2%) presenting optical
complaints and slight or moderate visual defects, some
of which were reported by the families as recent on-
set. In 10 cases (4.3%), there was late neuropsycho-
motor development, with five of them (2.4%) present-
ing convulsions, syncope and irritability. Of those
children with clinical abnormalities, 16 were born to
mothers with IgM indices between 0.600 and <1.000
(Table 3). Most of the mothers did not receive che-
moprophylaxis (Table 3). Treatment with spiramycin,
sulphadiazine, pyrimethamine and folinic acid was
started in two of the three children with serious opti-
cal lesions.
DISCUSSION
The 1.0% prevalence of pregnant anti-T. gondii-IgM-
reagent women among those attending public health
care services points out to the importance of ad-
equately diagnosing and monitoring congenital toxo-
plasmosis. The infection rate observed in the present
study is similar to those in other regions of the coun-
try, which ranged between 0.6 and 0.8%, even when
different study methods are used.11,16 Prospective stud-
ies by Spalding et al18 (2003) and Varella et al1 (2003)
in the state of Rio Grande do Sul have reported even
higher rates. According to Avelino et al1 (2003), preg-
nant women are twice as likely to show seroconver-
sion as are non-pregnant women, and seven times more
likely if they are adolescents living in environments
contaminated by the feces of host animals. Low in-
come and low education increase the risk of serocon-
version in women over 30 years of age. Contact with
contaminated soil or animals, ingestion of non-com-
mercially preserved food, living in rural areas, and
ingestion of raw water are factors that contribute to
infection.19
There were differences in the number of subjects stud-
ied for the several variables analyzed because of the
difficulty in obtaining information from records and
locating them for interviews.
The majority of women sought early prenatal care,
which is a precondition for effective monitoring of
maternal-infant health. However, the time required
for intervention may be affected by delays in collec-
tion of the first sample for the serology test, the fol-
low-up visit for interpretation of the result, the deci-
sion to prescribe chemoprophylaxis in each case, and
drug availability in the public health system. In moni-
tored assays, maternal infection occurred during a
period shortly before the last negative test or at any
Table 2 - Anti-T. gondii indices compared to treatment. State
of Paraná, Southern Brazil, January 2001 to December 2003.
Anti-T. gondii IgM Treatment Total
Yes No
0.600 to 1.000 63 86 149
1.000 to 2.000 32 23 55
Greater than 2.000* 17 6 23
Total 112 115 227
*p=0.0095
Table 3 - Clinical abnormalities in exposed children, mothers’ anti-T. gondii IgM indices, and maternal chemoprophylaxis.
State of Paraná, Southern Brazil, January 2001 to December 2003.
Clinical abnormalities in Mother anti-T. gondii IgM index* Chemoprophylaxis** Total
exposed children >0.600 to <1.000 ≥1.000 to < 2.000 ≥2.000 Yes No
Optical alterations 9 2 5 6 10 16
Late neuropsychomotor development 5 3 2 2 8 10
Hearing/speech alterations 2 1 1 1 3 4
Total 16 6 8 9 21 30
*p=0.905; **p=0.746
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time up until a short but unknown period before the
first positive IgM test.6 Therefore, congenital infec-
tion remains a concern despite intervention.
The laboratory diagnostic test used with the reagent
pregnant women and children exposed was based on
IgM and IgG antibodies. They are useful for the ini-
tial identif ication of pregnant women and new-
borns,11,18 and are advocated in the prenatal routine
of public health care services in the region. The fact
that IgM remains at high levels for many months,9
and the difficulty of accessing other laboratory tech-
niques, rendered serodiagnosis of acute toxoplasmo-
sis inadequate. One important aspect is the probable
occurrence of false-positive reactions in a certain pro-
portion of the population tested. Testing for anti-T.
gondii IgA was not carried out, though recommended
in the Protocol for High-Risk Pregnancy. The IgG
avidity test was only available to women who could
pay for it. The repetition of IgM and IgG tests with
two or three samples in some of the women reveals
the difficulty in following the protocol recommen-
dations, which suggests new serologies only for preg-
nant women who are IgM and IgG non-reagent. How-
ever, this procedure is inadequate due to the persist-
ence of the IgM antibodies and the waiting time for
results while the infection may be affecting the fetus.
A single IgM and IgG serology test supported the
majority of the decisions taken by the doctors re-
garding therapeutic and prophylactic management.
There is controversy over the serological tests used in
the diagnosis of acute toxoplasmosis in pregnancy
because decisions based on false-positive tests may
result in pregnancy interruption and unnecessary
treatment.9 Several studies have suggested the need
for using new serological markers for recent infec-
tions, such as IgA, IgE and IgG avidity tests and de-
tection of T. gondii by PCR.8,12,18 Clinical evidences
of toxoplasmosis were not common among the women
studied, and cannot always be correlated with rea-
gent serology. T. gondii infections may progress to
the sub-clinical form in 90% of cases, presenting non-
specific signs.14,22 One important finding was that
some women with visual disturbances reported dis-
ease recurrence after the birth, indicating the progress
of optical lesions, as reported by Gómez-Marín et al7
(2000). The suggestive ultrasonography alterations
did not always result in clinical, laboratory and thera-
peutic follow-up of the unborn children.
Only half of the study pregnant women received treat-
ment, even when complications were suspected. Some
studies12,16,22 have indicated that therapy can reduce
fetal infection in 35 to 60% of cases. Despite the large
number of studies over the last three decades, it is
still not known whether prenatal treatment of women
with presumed toxoplasmosis reduces congenital
transmission of T. gondii.* The prescribed therapy to
the studied women was not completed in all of those
who were treated. Some of the reasons for treatment
discontinuation were drug side effects, high costs,
and fetal loss. However, potentially beneficial or
harmful effects of treatment on the risk of clinical
signs in infected children cannot be excluded.20
Pregnant women with higher IgM indices tended to
be treated more frequently. Laboratory diagnosis,
clinical evidence and ultrasonography exams avail-
able were considered enough information for de-
tecting women with suspected infection and pro-
viding chemoprophylaxis. The present study showed
a lack of consensus among professionals regarding
treatment of pregnant women. Even those women
who showed low indices of IgM were treated with-
out carrying out other laboratory tests, although
such tests are recommended in the State Protocol.
One of the most serious problems was the lack of
flexibility in the operation of the laboratory exami-
nation-revisit-treatment follow-up of the system. The
problem of determining fetal infection was reflected
in the treatment, as different therapeutic regimens
were used. In few cases, a triple regimen (sulphadi-
azine, pyrimethamine and folinic acid, intercalated
with spiramycin) or the continuous use of spiramycin
alone until the end of gestation were prescribed –
both as proposed in the State Protocol. Couto et al3
(2003) emphasized the need to use spiramycin con-
tinuously until the end of pregnancy because of its
parasitostatic action on T. gondii, thereby reducing
the risk of vertical transmission.
It was not possible to determine the real prevalence
rate of congenital toxoplasmosis due to the small pro-
portion of children who underwent serological fol-
low-up. During their first year of life, almost all chil-
dren were followed up clinically but few were evalu-
ated for congenital toxoplasmosis. Thirty out of 208
children showed clinical symptoms suggestive of
congenital toxoplasmosis, including three confirmed
cases of retinochoroiditis, who lacked etiological
confirmation and adequate laboratory monitoring.
Of the latent complications, retinochoroiditis is the
main sequelae of infection in children. Retinoc-
horoiditis can appear years after birth, in adolescence
or in adulthood, drastically reducing visual acuity
and affecting their quality of life.15,18 Segundo et al15
(2004) observed retinochoroiditis in 2/805 newborns
who had anti-T. gondii IgA, highlighting the impor-
tance of clinical and laboratory follow-up.
*Peyron F, Wallon M, Liou C, Garner P. Treatments for toxoplasmosis in pregnancy. Cochrane Database Syst Rev. 2000;(2):CD001684.
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In order to reduce the vertical transmission of toxo-
plasmosis and prevent early and late complications
in children, it is essential public health care services
monitor the program. In addition to the recommended
procedures, there should be confirmatory diagnoses,
the integration of the various services providing care
to pregnant women and their newborns, and the avail-
ability of free therapy. There must be conditions to
effectively implement the State Protocol.
The present study showed that the recommendations
for monitoring this infection risk are not being sys-
tematically observed as some pregnant women with
suspect laboratory results were not duly investigated,
and some fetuses and newborns went without ad-
equate monitoring for up to 12 months. Confirmed
cases of congenital toxoplasmosis were detected only
after birth in children with evident clinical abnor-
malities and the presence of IgM. This study pointed
out to the need for implementing a surveillance sys-
tem in Brazil for pregnant women and newborns ex-
posed to T. gondii, as well as other infectious con-
genital diseases such as syphilis and HIV/AIDS.
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